


Public private partnership



This graphic above shows connections between the Gates Foundation, Wellcome Trust, WHO, GAVI and other NGOs and Big Pharma... It contains round about 6500 objects including like Persons, NGOs, Companies, Documents, etc. It also includes more than 7200 links between them.

All information is publicly available.


The following slides presents some selected organizations from this graphic. Cause of the complexity it shows mostly only the first level of connection.

First, you will get some general information about people from government agencies, companies and non-governmental organizations, as well as some important events or groups. Further on in this document you will find a link analysis of these "stakeholders".


The red lines are always payments, but there might be also some black lines are payments as well. Please see link description.

Please make your own opinion and do your own research!

2021-09-12



Grants from BMGF, Wellcome Trust and OP




Total Grants by Bill & Melinda Gates Foundation (1994-2021) - Top 50 Rows

Overview

Bill & Melinda Gates Foundation, Wellcome Trust, Rockefeller Foundation, World Economic Forum	6
GAVI, CEPI, COVAX, Find, The Global Fund	12
Direct Grants to Swiss Agency for Therapeutic Products, Charite, RKI - Robert Koch Institut, MHRA – Medicines & Healthcare products regulatory Agency and European Commission	23
Direct Grants to World Bank Group and KFW (Link Analysis)	28
Some “Public Websites”	33
Link Analysis	48
Link Analysis – Selected Views	81
IT	96
“EXERCISES”	99
“Meetings”	113
“Gang”	116
Sample of Public Private Partnership - Open Letter to Biden Administration – 3rd August 2021	125
Media	132
Misc	136
“Selected Person”	139

Bill & Melinda Gates Foundation (BMGF)

Direct connections (extract of entire link analysis)



Details you'll find in separate file: CorinaNetwork_GatesFoundationOnlyDirectConnections_2021-09-12.png

https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation

<https://www.gatesfoundation.org/>

<https://www.gatesfoundation.org/about/financials>

<https://www.gatesfoundation.org/about/committed-grants>

<https://www.gatesfoundation.org/philanthropypartners>

<https://www.gatesfoundation.org/goalkeepers/>

Bill & Melinda Gates Foundation Strategic Investment FUND

Portfolio (extract):

 1mg Technologies Private Limited 1mg Technologies Private Limited is a digital consumer healthcare platform in India that provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation invested in the Company to accelerate low-cost delivery of high-quality essential medicines and other. Read More
 Abbott Laboratories Abbott Laboratories received support from the foundation to make its Panbio COVID-19 Ag Rapid Test available to low- and middle-income countries. Making high-quality, affordable rapid diagnostic tests with results available in 15-20 minutes is critical in the fight to control. Read More
 Achaogen Achaogen is focused on R&D and commercialization of antibiotics to combat multi-drug resistant, Gram-negative infections. The foundation's investment is supporting the development of Achaogen's monoclonal antibody ("mAb") discovery platform. Press Release
 Acrobatic The foundation invested in Acrobatic, a leader in adaptive learning solutions, to support the growth of a next-generation adaptive learning, courseware, and analytics program. Press Release
 //Adjuvant Capital The foundation has committed to further support the Global Health Investment Fund model by investing as an anchor LP in Adjuvant. Adjuvant is a private investment fund focused on late-stage life sciences investments to address global health challenges. The Fund invests. Read More
 Affinivax Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine. News Story
 Africa Health Fund The foundation invested in the Africa Health Fund to provide capital to support new approaches to improving the quality and accessibility of private healthcare across the continent.
 African Agricultural Capital Fund The African Agricultural Capital Fund provides growth capital to companies that boost the productivity and profitability of smallholder farmers in East Africa. Press Release
 African Leadership Fund The African Leadership Foundation is a U.S. 501(c)(3) organization with a mission to educate Africa's next generation of young leaders. The foundation provided a loan to support the organization's 2020-2021 school year objectives. Investment Date: May 2020
 AgBiome AgBiome is focused on discovery and development of biological and transgenic products for crop protection. AgBiome identifies microbes from a wide variety of sources to harness their natural abilities to help crops resist pests and stresses. Press Release

1 2 3 ... 8 ►

 BioE Pharmaceutical company BioE identifies innovative approaches to reduce the cost of vaccine production. Press Release News Story
 BioNTech BioNTech is focused on combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The Foundation is working with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and tuberculosis infection as Read More Press Release
 bKash Through its mobile payments platform, bKash helps to ensure access to a broader range of financial services for the people of Bangladesh. Press Release News Story
 BloomBoard Software development company BloomBoard received funding from the foundation to help efforts in improving teachers' instructional practices. Press Release
 Butterfly Network Butterfly has created the world's first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation's vision of an ecosystem where hardware, software, data and expertise come together. Read More Press Release News Story
 CHAI (Clinton Health Access Initiative) The foundation provided a guarantee to CHAI to structure volume guarantees to reduce the price and increase access to life-saving commodities in the developing world.
 Charter School Growth Fund Facility Fund The Charter School Growth Fund provides strategic support to high-performing charter management organizations. Inclusive within its support, CSGF provided subordinated bridge loans to address the short-term financing gap CMOs face during construction.
 Charter School Growth Fund Facility Fund III As a follow-on to the CSGF Facility Fund, the organization created a new fund in 2016, to broaden their lending to include early-stage operators, provide more proactive technical assistance and partner with other key stakeholders to remove barriers to affordable charter facilities and financing.
 Civic Builders Funding from the foundation and New Markets Tax Credits, alongside support from Civic Builders, built new schools in a bankrupt city where facilities assistance was otherwise unavailable. Case Study
 ClinVet ClinVet specializes in conducting clinical trials to understand and improve veterinary health products. With the help of the foundation, ClinVet was able to construct a new facility in Morocco to expand its capabilities to conduct trials for livestock products.


◀ 1 2 3 4 5 ... 8 ►

 lumiraDx LumiraDx develops point-of-care diagnostics solutions on a portable, cloud-connected reader using finger-prick blood samples tested on disposable, microfluidic strips. The company is working to achieve lab-quality performance and health-IT integration at point-of-care settings globally. The foundation invested in the company Read More
 Lyndra Therapeutics Lyndra Therapeutics is developing an orally administered dosage form designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. The foundation invested in the company Read More Press Release
 M-KOPA M-KOPA is a Nairobi-based, off-grid solar energy company, which makes residential power systems affordable and accessible to low-income, off-grid customers through a mobile payment-based lease-to-own model. Press Release Case Study
 MEDICAL CREDIT FUND (MCF) AFRICA The Medical Credit Fund provides loans and technical assistance to small primary care clinics in Africa. Through the loan fund, MCF expanded its lending and technical assistance across Ghana, Nigeria, Kenya, and Tanzania. Press Release
 MERCK The foundation partnered with private and public organizations make Implanon NXT®, a single rod, long-acting, reversible contraceptive implant, available in the world's poorest countries at a more than 50 percent price reduction. Press Release Case Study
 Mylan Dolaggravir Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolaggravir to low- and middle-income populations at a low price. Press Release News Story
 OraSure The foundation invested in OraSure to secure a reduced price for the saliva-based HIV self-test OraQuick. Press Release News Story
 Owl Ventures Owl Ventures is a venture investment fund that leads Series A/B investments in US K-12 education technology companies.
 PAHO The Pan American Health Organization (PAHO) is an international public health agency working to improve health and living standards in America. Case Study
 Pfizer The foundation invested in Pfizer to expand access to the pharmaceutical company's all-in-one injectable contraceptive, Serafina, giving women in the developing world an affordable option.

◀ 1 ... 4 5 6 7 8 ►

Wellcome Trust

Direct connections (extract of entire link analysis)




<https://wellcome.org>

https://en.wikipedia.org/wiki/Wellcome_Trust

Rockefeller Foundation

Here you can see only a small excerpt of the Rockefeller Foundation. The Rockefeller Foundation's connections are actually much more far-reaching. No connections to other Rockefeller NGOs, such as Rockefeller Philanthropy Advisors, Rockefeller Brothers Fund, etc. are shown here.



<https://www.rockefellerfoundation.org/about-us/board-of-trustees/>

<https://www.rockefellerfoundation.org/grants/>

https://en.wikipedia.org/wiki/Rockefeller_Foundation

<http://www.nommeraradio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf>

"The World Economic Forum

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.

It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.

Our activities are shaped by a unique institutional culture founded on the stakeholder theory, which asserts that an organization is accountable to all parts of society. The institution carefully blends and balances the best of many kinds of organizations, from both the public and private sectors, international organizations and academic institutions.


We believe that progress happens by bringing together people from all walks of life who have the drive and the influence to make positive change.

Read the latest Annual Report [here](#). Find out about our Foundation [Regulations](#) and [Statutes](#).

<https://www.weforum.org/about/world-economic-forum>

"World Economic Forum Partners are leading global companies developing solutions to the world's greatest challenges. They are the driving force behind the Forum's programmes. Our Partners engage in Forum Platforms to shape the future, accessing networks and experts to ensure strategic decision-making on the most pressing world issues."


<https://www.weforum.org/partners>



<https://intelligence.weforum.org/topics/a1G0X000006O6EHUA0?tab=publications>

World Economic Forum (WEF)

Direct connections
(extract of entire link analysis)



GAVI, officially Gavi, the Vaccine Alliance


(previously the **GAVI Alliance**, and before that the **Global Alliance for Vaccines and Immunization**)

“GAVI facilitates vaccinations in developing countries by working with donor governments, the [World Health Organization](#),^[4] [UNICEF](#),^[5] the [World Bank](#),^[6] the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the [Bill & Melinda Gates Foundation](#)^[7] and other private philanthropists. GAVI has observer status at the [World Health Assembly](#).”

<https://en.wikipedia.org/wiki/GAVI>


„Die Impfallianz Gavi wurde am 29. Januar 2000 am **Weltwirtschaftsforum (WEF – World Economic Forum)** in **Davos** ins Leben gerufen.“

<https://www.savethechildren.de/news/20-jahre-im-einsatz-fuer-kinder-die-impfallianz-gavi/>



<https://www.gavi.org/our-alliance/about>

GAVI - Direct connections (extract of entire link analysis)



GAVI has full immunity in Switzerland

(Stand am 1. Januar 2009)

¹ Der Originaltext findet sich unter der gleichen Nummer in der französischen Ausgabe dieser Sammlung.

Der Schweizerische Bundesrat

einerseits

und

GAVI Alliance (Global Alliance for Vaccines and Immunization)

andererseits,

in dem Wunsche, ihre Beziehungen in einem Sitzabkommen zu regeln,

sind wie folgt übereingekommen:

- I. Statut, Vorrechte und Immunitäten von GAVI Alliance

- Art. 1 Persönlichkeit und Rechtsfähigkeit

Der Schweizerische Bundesrat anerkennt die internationale Rechtspersönlichkeit und die Rechtsfähigkeit von GAVI Alliance in der Schweiz.

- Art. 2 Unabhängigkeit und Handlungsfreiheit

1. Der Schweizerische Bundesrat garantiert GAVI Alliance Unabhängigkeit und Handlungsfreiheit.

2. Er gewährt ihr die uneingeschränkte Versammlungsfreiheit, einschliesslich der Rede-, Beschluss- und Publikationsfreiheit, auf dem Hoheitsgebiet der Schweiz.

- Art. 3 Unverletzbarkeit der Räumlichkeiten

Die Gebäude oder Gebäudeteile und das anliegende Gelände, die von GAVI Alliance für ihre eigenen Zwecke benützt werden, sind ungeachtet der herrschenden Eigentumsverhältnisse unverletzbar. Kein Vertreter schweizerischer Behörden darf sie ohne ausdrückliche Zustimmung des Exekutivdirektors von GAVI Alliance oder der von ihm bezeichneten Person betreten.

- Art. 4 Unverletzbarkeit der Archive

Die Archive von GAVI Alliance und alle ihr gehörenden oder in ihrem Besitz befindlichen Dokumente und Datenträger ganz allgemein sind jederzeit und überall unverletzbar.

- Art. 5 Immunität von der Gerichtsbarkeit und der Vollstreckung

1. Im Rahmen ihrer Tätigkeit geniesst GAVI Alliance Immunität von der Gerichtsbarkeit und der Vollstreckung, ausser:

- a) wenn diese Befreiung im Einzelfall vom Exekutivdirektor oder durch die von ihm bezeichnete Person ausdrücklich aufgehoben worden ist;
- b) im Falle einer gegen GAVI Alliance angestrengten zivilrechtlichen Haftungsklage wegen eines Schadens, der durch ein GAVI Alliance gehörendes oder auf ihre Rechnung betriebenes Kraftfahrzeug verursacht wurde;
- c) im Falle einer durch richterlichen Entscheid angeordneten Beschlagnahme von Gehältern, Löhnen und anderen Bezügen, welche GAVI Alliance einem ihrer Beamten schuldet;
- d) im Falle einer Widerklage, die in unmittelbarem Zusammenhang mit einer von GAVI Alliance erhobenen Hauptklage steht; und
- e) im Falle der Vollstreckung einer schiedsrichterlichen Entscheidung, welche in Anwendung von Artikel 29 dieses Abkommens gefällt wurde.

2. Die Gebäude oder Gebäudeteile, das anliegende Gelände sowie die Vermögenswerte, die sich im Eigentum von GAVI Alliance befinden oder von ihr zu ihren Zwecken benutzt werden, sind unabhängig von ihrem Standort und ihrem Besitzer befreit von:

- a) jeglicher Form von Requisition, Beschlagnahme oder Enteignung;
- b) jeglicher Form von Zwangsvollstreckung, anderen behördlichen Zwangsmassnahmen oder Massnahmen, die einem Urteil vorausgehen, mit Ausnahme der in Absatz 1 vorgesehenen Fälle.

- Art. 6 Veröffentlichungen und Mitteilungen

Abkommen

zwischen dem **Schweizerischen Bundesrat** und **GAVI Alliance**
(Global Alliance for Vaccines and Immunization) zur Regelung
des rechtlichen Status von GAVI Alliance in der Schweiz

<https://www.fedlex.admin.ch/eli/cc/2009/541/de>

CEPI - Coalition for Epidemic Preparedness Innovations


CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome.

<https://cepi.net/about/whowear/>



CEPI - Coalition for Epidemic Preparedness Innovations




CEPI - Coalition for Epidemic Preparedness Innovations

This link analysis shows direct path of people are shown in previous graph.

Please have a look at separate file:

Corina_Network_CEPI_PeopleAndThei
rDirectPath_2021-09-12.png



FIND

“FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world.

We connect countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.

We are working to save 1 million lives through accessible, quality diagnosis, and save US\$1 billion in healthcare costs to patients and health systems. We are co-convener of the [Access to COVID-19 Tools \(ACT\)](#)


[Accelerator](#) diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic”

<https://www.finddx.org/about/>

<https://www.finddx.org/>

<https://dndi.org/press-releases/2010/international-status-granted/>

https://en.wikipedia.org/wiki/Foundation_for_Innovative_New_Diagnostics



COVAX / ACT-A




With a fast-moving pandemic, no one is safe, unless everyone is safe

COVAX is co-led by [CEPI](#), [Gavi](#) and WHO, alongside key delivery partner [UNICEF](#). In the Americas, the PAHO Revolving Fund is the recognized procurement agent for COVAX.



<https://www.who.int/initiatives/act-accelerator/covax>
<https://www.gavi.org/vaccineswork/covax-explained>
<https://en.wikipedia.org/wiki/COVAX>



2,2 Milliarden Euro für Impfungen, Diagnostik und Medikamente

Die Pandemie kann nur besiegt werden, wenn sie weltweit unter Kontrolle gebracht wird: Deutschland hat sich deshalb schon früh für eine gemeinsame und solidarische Antwort auf die Pandemie stark gemacht. Nach dem Grundsatz „Niemand ist sicher, bis alle sicher sind“ hat Deutschland im vergangenen Jahr den Koordinierungsmechanismus Access to Covid-19 Tools Accelerator (ACT-A) mitgegründet. Als derzeit zweitgrößter Geber von ACT-A hat Deutschland bislang 2,2 Milliarden Euro zur Verfügung gestellt. Der Großteil der Unterstützung geht an die internationale Impfstoffplattform COVAX, ein Teil wird auch für Diagnostik und Medikamente gegen die Krankheit verwendet. Bis Anfang August wurden dadurch bereits 138 Staaten mit insgesamt über 200 Millionen Dosen der Impfstoffe von AstraZeneca, Johnson & Johnson, Moderna und BioNTech versorgt.

Auszug aus <https://www.auswaertiges-amt.de/de/aussenpolitik/themen/gesundheit/covax/2395748> vom 26.08.2021

Weiterführende Links:

<https://www.who.int/initiatives/act-accelerator>
<https://www.gavi.org/covax-facility>

The Global Fund

„Der **Globale Fonds zur Bekämpfung von AIDS, Tuberkulose und Malaria** ([englisch The Global Fund to Fight AIDS, Tuberculosis and Malaria](#), kurz GFATM) mit Sitz in [Genf, Schweiz](#), ist ein Finanzierungsinstrument zur Bekämpfung der drei großen Infektionskrankheiten [AIDS](#), [Tuberkulose](#) und [Malaria](#). Der weltweit in mehr als 100 Ländern tätige Fonds ist eines der wichtigsten Instrumente zur Bekämpfung dieser Krankheiten.“

„Der Fonds wurde im Jahr 2002 gegründet, nachdem sich die [G8](#)-Staaten auf ihrem [Treffen in Genua 2001](#) darauf verständigt hatten, die Finanzierung des weltweiten Kampfes gegen die drei schweren Infektionskrankheiten AIDS, Tuberkulose und Malaria zu verstärken. Schon ein Jahr zuvor forderte der ehemalige [UN-Generalsekretär Kofi Annan](#) die Einrichtung eines solchen Fonds^[2]. Der Fonds dient der Finanzierung nationaler Maßnahmen gegen die drei Krankheiten einschließlich der Stärkung von Gesundheitssystemen. Er fördert zudem die Eigenverantwortung der Regierungen, die Mitwirkung der Zivilgesellschaft und des privaten Sektors sowie wirkungs- und genderorientierte Maßnahmen gegen Aids, Tuberkulose und Malaria. Der ehemalige Leiter des US-AIDS-Programms PEPFAR (President's Emergency Plan for AIDS Relief), Mark Dybul, wurde im Jahre 2012 zum Leiter des Globalen Fonds gewählt. Er hatte dieses Amt bis Mai 2017 inne. Mark Dybul gilt in Fachkreisen als Visionär im Bereich globaler Gesundheit und hatte maßgeblich an der Gründung und Durchführung des Notfallplans des US-Präsidenten für AIDS-Bekämpfung (PEPFAR) beigetragen. Als Arzt mit dem Schwerpunkt Immunologie wurde er als Mediziner, Wissenschaftler und strategisch denkender Verwalter zum ausgewiesenen HIV- und AIDS-Experten. Nach dem Abschied von Mark Dybul leitete Marijke Wijnroks vorübergehend die Organisation. Seit März 2018 ist [Peter Sands](#) Direktor des GFATM.“

„Deutschland und der Globale Fonds

Als viertgrößter Geber (nach den USA, Frankreich und Großbritannien) leistet Deutschland einen bedeutenden Beitrag zur weltweiten Bekämpfung von AIDS, Tuberkulose und Malaria.^[13] Zudem spielt das Land als Mitglied des Verwaltungsrats eine entscheidende Rolle dabei, den globalen Fonds bei der Umstrukturierung und Straffung von dessen Betriebsabläufen zu unterstützen, damit die Investitionen der Organisation durchdacht getätigten werden und auf maximale Wirkung ausgerichtet sind. Außerdem hat der Fonds ein neues Finanzierungsmodell eingeführt. Durch das neue Finanzierungsmodell wird eine stärkere Verantwortung der Länder für Projekte gefördert. Zudem wirkt das neue Finanzierungsmodell als Anreiz für politischen Dialog mit den Programmdurchführungs ländern und zielt gleichzeitig auf die Berücksichtigung von Themen der Gleichberechtigung von Männern und Frauen sowie der sexuellen und reproduktiven Gesundheit und von Menschenrechtsbelangen ab. Der Landesdialog als Schlüsselement des neuen Finanzierungsmodells bietet außerdem neue Chancen für das Engagement aller Partner, auch aus der Zivilgesellschaft und der freien Wirtschaft. Neben diesen Beiträgen ist Deutschland auch einer der führenden Schirmherren des Programms Debt2Health des Globalen Fonds, das weltweit zu einem erheblichen Anstieg der Förderung von Programmen des Globalen Fonds geführt hat. Im Rahmen dieser Initiative hat Deutschland in Ländern wie Côte d'Ivoire, Indonesien, Pakistan und Ägypten einen Schuldenschnitt vorgenommen.“

https://de.wikipedia.org/wiki/Global_Fund

https://en.wikipedia.org/wiki/The_Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria

<https://www.theglobalfund.org/en/overview/>


<https://www.theglobalfund.org/en/>

<https://www.theglobalfund.org/en/board/>

<https://www.theglobalfund.org/en/private-ngo-partners/resource-mobilization/bill-melinda-gates-foundation/>

The Global Fund

TheGlobalFund



Direct grants from Bill & Melinda Gates Foundation (BMGF) to

- Swiss Agency for Therapeutic Products, Switzerland
- Charite, Germany
- RKI - Robert Koch Institut, Germany
- MHRA – Medicines & Healthcare products regulatory Agency, United Kingdom
- European Commission

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending ▾

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Therapeutic Products	Global Health	FEBRUARY 2020	GLOBAL +1	\$900,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Development of Solutions to Improve Global Health	46	Berne, Switzerland	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Therapeutic Products	Global Health	DECEMBER 2015	GLOBAL +1	\$1,332,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Development of Solutions to Improve Global Health	67	Berne, Switzerland	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Development and Cooperation	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL +2	\$453,381
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Water, Sanitation and Hygiene	48	Bern, Switzerland	

<https://www.gatesfoundation.org/about/committed-grants?q=Swiss%20Agency><https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/internationale-zusammenarbeit/multilaterale-zusammenarbeit-mit-internationalen-organisationen-/bill-and-melinda-gates-foundation.html>

Show 10 ▾

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending ▾

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	MARCH 2020	GLOBAL	\$249,550
GRANTEE	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Charité - Universitätsmedizin Berlin	Support Innovative Technology Solutions	40	Berlin, Germany	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	DECEMBER 2019	GLOBAL	\$86,181
GRANTEE	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Charité - Universitätsmedizin Berlin	Pneumonia	4	Berlin, Germany	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Policy and Advocacy	OCTOBER 2018	GLOBAL	\$549,999
GRANTEE	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Charité - Universitätsmedizin Berlin	Global Health and Development Public Awareness and Analysis	14	Berlin, Germany	

<https://www.gatesfoundation.org/about/committed-grants?q=Charit%C3%A9>

Date Last Updated: 8.23.2021

Committed Grants; sort by Date Descending

Date Descending ▾

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Robert Koch Institute	Global Health	NOVEMBER 2019	GLOBAL	\$253,000
GRANTEE	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
Robert Koch Institute	Vaccine Development	59	Berlin, Berlin, Germany	

Show 10 ▾

<https://www.gatesfoundation.org/about/committed-grants?q=robert%20koch>

MHRA awarded over £980,000 for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation

MHRA today announced a partnership worth over £980,000 to improve the safety monitoring of medicines in low and middle-income countries.

From: [Medicines and Healthcare products Regulatory Agency](#)

Published 15 December 2017



Medicines & Healthcare products Regulatory Agency

We are delighted to announce a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation that aims to extensively improve the safety monitoring of medicines in low and middle-income countries (LMIC).

New medicines and vaccines, for diseases such as malaria and HIV, may be introduced for the first time in LMIC's where there are weak or no regulatory

<https://www.gov.uk/government/news/mhra-awarded-over-980000-for-collaboration-with-the-bill-and-melinda-gates-foundation-and-the-world-health-organisation>

MHRA and the Bill & Melinda Gates Foundation to look at the safer, effective use of medicines during pregnancy

MHRA and the Bill & Melinda Gates Foundation have begun new research on medicine use which could impact the health of pregnant women around the world.

From: [Medicines and Healthcare products Regulatory Agency](#)

Published 17 September 2019



Related content

[Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy](#)

[Report of the Commission on Human Medicines' Expert Working Group on Hormone Pregnancy Tests](#)

[Safer Medicines in Pregnancy and Breastfeeding Consortium](#)

[Epilepsy medicines and pregnancy](#)

Brexit

[Check what you need to do](#)

Brexit

[Check what you need to do](#)

In advance of World Patient Safety Day (17 September), MHRA specialists, as part of a broader programme of work, have begun developing ground-breaking research to support the safer use of medicine during pregnancy.

A \$360,000 grant over two years from the Bill & Melinda Gates Foundation (approximately £292,000), will support the MHRA's research, to help predict the need for adjusting a medicine's dose during different trimesters of pregnancy. This will ensure effective use, which is vitally important for the health of mother and baby.

Worldwide, data in this area remain limited, and new insights could potentially impact the health of pregnant women around the world. This would also give obstetricians further clarity on the optimal dose of a

<https://www.gov.uk/government/news/mhra-and-the-bill-melinda-gates-foundation-to-look-at-the-safer-effective-use-of-medicines-during-pregnancy>

Committed Grants; sort by Date Descending

Date Descending



GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Commission	Global Development	MARCH 2020	GLOBAL +1	\$500,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Nutrition	17	Brussels, Belgium	
European Commission	Global Health	MARCH 2019	GLOBAL +1	\$45,178,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Development of Solutions to Improve Global Health	238	Brussels, Belgium	
European Centre for Development Policy Management	Global Policy and Advocacy	MARCH 2017	GLOBAL	\$399,982
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Global Health and Development Public Awareness and Analysis	25	Maastricht, Netherlands	
European Commission	Global Development	FEBRUARY 2016	GLOBAL +2	\$500,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Nutrition	22	Brussels, Belgium	
Imperial College London	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL +1	\$2,692,835
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Agricultural Development	40	London, United Kingdom	

<https://www.gatesfoundation.org/about/committed-grants?q=european%20commission>



<https://www.worldbank.org/en/topic/financialinclusion/overview#4>


https://www.globalfinancingfacility.org/sites/gff_new/files/documents/GFF-IG1-2_Participant%20List%209_25.pdf

The World Bank Group works globally with standard-setting bodies to develop guidelines, standards and good practices. We also work with the G20 to develop guidance for regulators and policymakers and to catalyze new actions in support of financial inclusion. We are also an implementing partner for the G20 Global Partnership for Financial Inclusion (GPFI).


We also work closely with a number of organizations and donor partners to advance financial inclusion, including Alliance for Financial Inclusion (AFI), AusAid, the Bill and Melinda Gates Foundation, DFID, Financial Sector Development Trusts, GIZ, the Ministry of Foreign Affairs of the Netherlands, the OECD, SECO, UNCDF, UNCITRAL, UNSGSA, USAID, and regional development banks.

The Ministry of Foreign Affairs of the Netherlands and the Bill and Melinda Gates Foundation provide the funding for the Financial Inclusion Support Framework (FISF), while SECO provides funding for the Consumer Protection and Financial Literacy (CPFL) program, and DFID provides funding for the Harnessing Innovation for Financial Inclusion (HiFi) program.


World Bank




IFC International Finance Corporation (World Bank)



GFF – Global Financing Facility (World Bank)





Some “Public Websites”

Please look at the people and organizations.
You'll find some of them later in several link analysis.

Mai 2017 / August 2018

Four new members complete the International Advisory Board on Global Health

<https://www.bundesgesundheitsministerium.de/english-version/press/2018/international-advisory-board.html>



Meeting in July with some members of the IAB and two Secretary of States (from left to right: Farrar, Roses, Hacker, Kickbusch, Secretary of State Stroppe, Nishtar, Elias, Schneider, Secretary of State Flachsbarth, Benn)

The Advisory Board consists of ten German and international experts. Six members of the International Advisory Board on Global Health have already been appointed by the Federal Ministry of Health in August 2017. Another four were appointed as members in May 2018. The Board now includes experts from different regions and stakeholder groups that have extensive expertise on various global health topics.

Members of the International Advisory Board on Global Health

- Prof Dr Ilona Kickbusch, Director of the Global Health Centre at the Graduate Institute of International and Development Studies, Geneva (Chair of the board)
- Prof Dr Christian Drosten, Chair of the Institute of Virology at the Charité Berlin
- Dr Christopher Elias, President of the Global Development Program, Bill & Melinda Gates Foundation
- Dr Jeremy Farrar, Director of the Wellcome Trust
- Prof Dr Jörg Hacker, President of the German National Academy of Sciences Leopoldina
- Dr Matshidiso Rebecca Moeti, WHO Regional Director for Afrika
- Dr Mirta Rosas Periago, former Director of the Pan American Health Organization
- Dr Sania Nishtar, President of Heartfile
- Dr Gisela Schneider, Director of the German Institute for Medical Mission
- Dr Christoph Benn, Director for External Relations of the Global Fund to Fight AIDS,

May 2018

WHO Global Preparedness Monitoring Board

The Global Preparedness Monitoring Board is a joint arm of the WHO and the World Bank.

Created in response to recommendations by the UN Secretary General's [Global Health Crises Task Force in 2017](#), the GPMB was co-convened by the World Health Organization and the World Bank Group and formally launched in May 2018

<https://apps.who.int/gpmb/>

Co-chairs



Dr Victor Dzau

President of the US National Academy of Medicine, USA

Board Members



Dr Chris Elias


President, Global Development Program, Bill & Melinda Gates Foundation, USA

Co-conveners



Sir Jeremy Farrar

Director, Wellcome Trust, UK



Dr Anthony S Fauci

Director, National Institute of Allergy and Infectious Diseases, USA



Ms Henrietta Fore

Executive Director, UNICEF



Dr George F. Gao

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



H.E. Sigrid Kaag

Minister for Foreign Trade and Development Cooperation, The Netherlands



Prof Ilona Kickbusch

Chair of the International Advisory Board of the Global Health Centre at the Graduate Institute of International



Dr Ngamije M. Daniel

Minister of Health, Republic of Rwanda

Alle Referenten

**Hermann Gröhe**Stellvertretender Vorsitzender der CDU/CSU-Bundestagsfraktion |
Beauftragter für Kirchen und Religionsgemeinschaften**Ralph Brinkhaus**

Vorsitzender der CDU/CSU-Fraktion im Deutschen Bundestag

**Dr. Angela Merkel**

Bundeskanzlerin der Bundesrepublik Deutschland

**Prof. Ilona Kickbusch PHD**Graduate Institute of International and Development Studies
Geneva

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Dr. Tedros Adhanom Ghebreyesus**

Generaldirektor der Weltgesundheitsorganisation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Prof. Dr. Christian Drosten**

Institut für Virologie Charité – Universitätsmedizin Berlin

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Prof. Dr. Clarissa Prazeres da Costa**Institut für Medizinische Mikrobiologie, Immunologie und Hygiene |
Technische Universität München

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Joe Cerrell**Geschäftsführender Direktor Globale Politik | Bill and Melinda Gates
Foundation

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Prof. Jeremy Farrar**

Direktor Wellcome Trust

Letzte Veranstaltung 08.05.2019 - 14:30

> Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

**Dr. Georg Kippels****Jens Spahn**

Bundesminister für Gesundheit

8. Mai 2019**CDU Veranstaltung – Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen**<https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten>

Global Health Hub Germany

The Global Health Hub Germany is a network that aims to bring together all actors interested in Global Health. The Hub wants to promote exchange, initiate new partnerships, support cooperation and innovative approaches - across sectors and stakeholder groups.

Membership is open to both individuals and organizations from all areas and sectors involved in Global Health - stakeholders from science, the private sector, civil society and politics, as well as from the health, environment, climate, food, agriculture, education and research sectors.

The Hub was inaugurated by Minister of Health Jens Spahn in February 2019 with a kick-off event at the Federal Ministry of Health. The Ministry of Health is providing funding for three years (2019-2021) for the set-up of the Hub and the establishment of the office.

Since the kick-off, the number of members has increased continuously: more than 1150 individuals and organizations have by now registered to make new contacts, exchange views on current issues and work together.


To promote cooperation and exchange, the Hub offers various possibilities and formats:

- Members can collaborate in cross-sectoral and cross-actor working groups on issues of their choice. Approximately 20 working groups have already been established on topics such as "Universal health coverage through digital technology", "Climate and Health" or "Global Mental Health". In the "Virtual Working Space", in the members only area of the website, interested members can join the already existing working groups to collaborate and discuss. Your topic is not included yet? No problem, you can suggest a new working group and search for fellow members who are interested in working on the same topic.
- With different types of events the Hub promotes regular exchange between members. In addition to face-to-face events, such as the annual Global Health Talk, webinars are held regularly to discuss current topics or present the work of the members.
- All registered members can be found in the member database in the members only area of the website. There you can search for experts on specific topics or from specific stakeholder groups. You can send networking requests, exchange views and discuss via the website by using the chat feature.
- In an interactive forum all members can informally exchange information, ask questions or give advice.

<https://www.globalhealthhub.de/index.php/en/content/about-hub>

The screenshot shows the Global Health Hub Germany website. At the top, there is a navigation bar with links for 'ABOUT', 'EVENTS CALENDAR', 'NEWS', 'WORKING GROUPS', 'LOGIN' (in a red box), 'REGISTER' (in a red box), and language options 'EN' and 'DE'. Below the navigation, the title 'Steering Committee' is displayed in large blue text. A decorative pattern of small triangles runs along the bottom of the page. At the bottom left, under the heading 'Foundations', there is a list of two names: 'Caroline Schmutte, Wellcome Trust' and 'Tobias Kahler, Bill & Melinda Gates Foundation'. At the very bottom right, there is a link 'https://www.globalhealthhub.de/en/content/steering-committee'.

Global Health Hub Germany



Advisory Board on Global Health (Germany)

Jens Spahn

29. Juli 2019

<https://www.globalhealthhub.de/en/news/international-advisory-board-germanys-opportunities-shaping-global-health>



29 JUL. 2019 | GLOBAL | BY: JULIA SCHMIDT

Event 201

18. Oktober 2019

<https://www.centerforhealthsecurity.org/event201/>

Players:

<https://www.centerforhealthsecurity.org/event201/players/index.html>

Video posted by John Hopkins University:

<https://www.youtube.com/watch?v=AoLw-Q8X174&list=PL9-oVXQX88esnrundaiuRdXGG7XOVYB9Xm>



Event 201 was supported by funding from the Open Philanthropy Project.

<https://www.centerforhealthsecurity.org/event201/about>



Latoya Abbott



Sofia Borges



Brad Connell



Christopher Elias



Tim Evans



George Gao



Avril Haines



Jane Halton



Matthew Harrington



Martin Knuchel



Eduardo Martinez



Stephen Redd



Hasti Taghi



Adrian Thomas



Lavan Thiru

World Health Summit

Berlin, Germany

#WHS2021 SPEAKERS



See more

<https://www.worldhealthsummit.org/summit/speakers.html>



OCTOBER 24-26, 2021
BERLIN, GERMANY & DIGITAL
SCIENCE · INNOVATION · POLICIES

SUMMIT 2021 ABOUT PARTNERS INITIATIVES M8 ALLIANCE NEWSROOM COMMUNITY COVID-19 PLATFORM

REGIONAL MEETINGS

Home > Partners > Sponsoring Partners

Search



SPONSORING AND SUPPORTING PARTNERS

STRATEGIC PARTNERS



MAJOR PARTNERS



GENERAL PARTNERS



SUPPORTING PARTNERS



NEWSLETTER

Get insights on global health, read about M8 Alliance and community activities, and stay up-to-date with the World Health Summit program: Sign up for our newsletter here

PATRONS 2021

The World Health Summit is traditionally held under the patronage of:

Angela Merkel
Chancellor of the Federal Republic of Germany

Emmanuel Macron
President of the French Republic

Ursula von der Leyen
President of the European Commission

Tedros Adhanom Ghebreyesus
Director-General of the World Health Organization (WHO)

KAMPALA DECLARATION

The World Health Summit Regional Meeting in Uganda ended with the Kampala Declaration on COVID-19 Vaccine Equity, signed by the Director-General of WHO, the President of Uganda, several ministers from Africa, the M8 Alliance, and the World Health Summit.

Find the declaration and all details on the Regional Meeting [here](#)



M8 ALLIANCE EXPERT MEETINGS 2021

Next Webinar: November 30, 2021

More information

WORLD HEALTH SUMMIT PRESIDENT


Axel R. Pries, Dean of Charité - Universitätsmedizin Berlin is World Health Summit President since 2021.

Read more

41

<https://www.worldhealthsummit.org/partner/sponsoring-partners.html>

Jens Spahn, CDU, Bundesgesundheitsminister



<https://www.tagesspiegel.de/politik/privater-immobiliendeal-des-gesundheitsministers-jens-spahn-ist-seiner-verantwortung-nicht-gerecht-geworden/26741038.html>

<https://www.spiegel.de/politik/deutschland/jens-spahn-villa-in-berlin-dahlem-kostete-4-125-millionen-euro-a-d8a665b4-4746-4ce8-898b-a1eb6713b0dd>

https://lobbypedia.de/wiki/Jens_Spahn

https://de.wikipedia.org/wiki/Jens_Spahn <https://cdn.businessinsider.de/wp-content/uploads/2021/04/Liste.pdf> (Jens Spahn - please see page 4 and 5)

PANORAMA

CORONAVIRUS-LIVETICKER CORONAVIRUS: ALLE KARTEN UND ZAHLEN

WELT+ PETER PIOT

„Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können“

Veröffentlicht am 13.05.2020 | Lesezeit: 4 Minuten

Von Cornelia Karin Hendrich
Redakteurin



Peter Piot warnt: Das Coronavirus sei eine "lebensverändernde Erfahrung".
Quelle: FABRICE COFFRINI/AFP via Getty Images

Einen Hauch des Todes habe er bei seiner Begegnung mit Covid-19 gespürt, sagt Peter Piot. Der Arzt und Wissenschaftler berät Ursula von der Leyen, zuletzt war er selbst an Corona erkrankt. Ohne Impfstoff werde es kein normales Leben mehr geben.

Der Wissenschaftler und Arzt Peter Piot, Miteinsteiger des Ebola-Virus, hat nach seiner eigenen Erkrankung mit Covid-19 vor Langzeitfolgen des neuartigen Coronavirus für viele Menschen gewarnt. Der vielfach ausgezeichnete Forscher, der auch Sonderberater der Präsidentin der EU-Kommission, Ursula von der Leyen, ist, sagte: „Es wird weltweit Hunderttausende von Menschen geben, möglicherweise mehr, die für den Rest ihres Lebens Behandlungen wie eine Dialyse benötigen.“

<https://www.welt.de/vermisches/plus207946977/Peter-Piot-Ohne-einen-Coronavirus-Impfstoff-werden-wir-nie-wieder-normal-leben-koennen.html>

European Commission

Home > Research and Innovation > Events > Upcoming events > European Research and Innovation Days > Speakers > Peter Piot

Peter Piot

Peter Piot is the Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on COVID-19. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008. He co-discovered the Ebola virus in 1976 and conducted pioneering research on HIV/AIDS.

Organization
London School of Hygiene & Tropical Medicine

Position
Director



See all speakers

Share this page

[Twitter](#) [Facebook](#) [LinkedIn](#) [E-mail](#) More share options

European Commission website
This site is managed by the Directorate-General for Research and Innovation

More information on:
Strategy About the European Commission Aid, Development cooperation, Fundamental rights
Food, Farming, Fisheries Business, Economy, Euro EU regional and urban development

<https://ec.europa.eu/research-and-innovation/en/events/upcoming-events/research-innovation-days/speakers/peter-piot>
https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Piot_Peter_EN.pdf

Menu

BILL & MELINDA GATES foundation

Home Ideas Media Center Dr. Peter Piot Joins Foundation as a Senior Fellow

Dr. Peter Piot Joins Foundation as a Senior Fellow - Bill & Melinda Gates Foundation

Media contact

Bill & Melinda Gates Foundation
Phone: +1.206.709.3400
Email: media@gatesfoundation.org

SEATTLE -- The Bill & Melinda Gates Foundation announced today that Peter Piot, M.D., Ph.D., has joined the foundation's Global Health Program as a senior fellow until April 30. A distinguished academic and accomplished leader in the global effort to fight HIV/AIDS, Piot served from 1995 to 2008 as the founding executive director of the Joint United Nations Program on HIV/AIDS (UNAIDS).

"Peter is a rigorous scientist and a passionate advocate for global health," said Dr. Tachi Yamada, president of the foundation's Global Health Program. "The foundation and our partners will benefit greatly from his deep experience and his insight into the health challenges facing developing countries."

As a senior fellow, Piot will advise the foundation on its global health strategy, including its support for efforts to fight HIV/AIDS and other infectious diseases.


"I am encouraged by the growing enthusiasm and support for improving health in the developing world," said Dr. Piot. "The Gates Foundation has played a central role in making this progress possible, and I look forward to working closely with my colleagues at the foundation to build on this momentum."

While at UNAIDS, Piot built a broad international coalition against the global HIV/AIDS epidemic, including both governments and civil society groups. He successfully advocated for increased funding for and attention to the epidemic. Global investments to fight HIV/AIDS grew from \$250 million in 1996 to \$10 billion in 2007.


Piot holds a medical degree from the University of Ghent in Belgium. In 1976, while in Zaire pursuing his Ph.D. in microbiology, he co-discovered the Ebola virus. Piot has held several academic positions and pioneered a series of collaborative programs in sub-Saharan Africa, including Project SIDA in Kinshasa, Zaire, the first international program on HIV in Africa.

<https://www.gatesfoundation.org/ideas/media-center/press-releases/2009/01/dr-peter-piot-joins-foundation-as-a-senior-fellow>

Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA



Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), Lothar Wieler, Christian Drosten



Hans-Ulrich Holtherm - Neu im Bundesgesundheitsministerium – 03/2020

aerzteblatt.de

Für Autoren ePaper

Arzteleb / cme / Ärztestellen / Studieren / English Edition

Home Archiv News Themen DÄ plus Politik Medizin

Archiv > Deutsches Arzteleb > 11/2020 > Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

PERSONALIEN

Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

Dtsch Arzteleb 2020; 117(11): A-557 / B-481

Beerheide, Rebecca



Artikel Briefe & Kommentare Statistik

Seit dem 1. März leitet Generalarzt Dr. med. Hans-Ulrich Holtherm (55) die im Bundesgesundheitsministerium (BMG) neu geschaffene Abteilung 6 „Gesundheitsschutz, Gesundheitssicherheit, Nachhaltigkeit“. In der Abteilung gibt es zwei Unterabteilungen mit jeweils fünf Fachreferenten, dazu zählen Referate zum nationalen und internationalen Krisenmanagement.

„Dr. Hans-Ulrich Holtherm verbindet durch seine langjährigen Erfahrungen die Themen Gesundheit und Sicherheit im gesamtgesellschaftlichen Ansatz und ist daher Sinnbild für die neue Abteilung 6“, heißt es zur Personale aus dem Ministerium. Der Kommandeur und Ärztliche Direktor des Bundeswehrkrankenhauses Ulm, bei dem er seinen Dienst erst im Januar 2020 antrat, sei Experte in Fragen des öffentlichen Gesundheitsdienstes im Inland sowie durch Erfahrungen mit der Bundeswehr im Ausland auch „sachkundig in der Krisenreaktion und -prävention“, so das BMG. Die Gründung dieser neuen Abteilung wurde schon 2019 beschlossen.

Anzeige



Hans-Ulrich Holtherm,
Foto: Bundeswehr

Holtherm war bei Auslandseinsätzen im Irak, Afghanistan, im Kongo, in Dschibuti und im Kosovo. Der Generalarzt war bereits 2009 im Zuge der H1N1-Pandemie von der Bundeswehr abgeordnet in das BMG und gehörte auch 2014 dem ressortübergreifenden Ebola-Krisenstab an. 1964 in Rheyne geboren, trat er 1983 in die Bundeswehr ein und studierte als Sanitätsoffiziersanwärter in Münster Humanmedizin. Er ist Allgemeinmediziner, Facharzt für Öffentliches Gesundheitswesen mit Zusatzqualifikationen in Tropen-, Flug- und Betriebsmedizin. Rebecca Beerheide

<https://www.aerzteblatt.de/archiv/213019/Hans-Ulrich-Holtherm-Neu-im-Bundesgesundheitsministerium>

https://de.wikipedia.org/wiki/Hans-Ulrich_Holtherm

Paul Zubeil - Neu im Bundesgesundheitsministerium – 02/2021

Paul Zubeil

Ehemann von Hendrik Streeck tritt Stelle im Bundesgesundheitsministerium an

8. Februar 2021 um 16:07 Uhr | Lesedauer: 5 Minuten



Das Bundesgesundheitsministerium hat seinen Sitz in Bonn. Foto: Benjamin Westhoff

Bonn. Der Ehemann des Bonner Virologen Hendrik Streeck, Paul Zubeil, hat am Montag eine Stelle im Bundesgesundheitsministerium am Dienstort Bonn angetreten. Er ist dort Unterabteilungsleiter für europäische und internationale Angelegenheiten.

https://ga.de/bonn/stadt-bonn/partner-von-hendrik-streeck-paul-zubeil-arbeitet-fuer-das-bundesgesundheitsministerium_aid-56131801

Auszug BioNTech – Geschäftsbericht 2019



Unsere Kollaborationen in den Bereichen Infektionskrankheiten und seltene Erkrankungen

Genevant

- Seit 2018 Co-Entwicklungs- und -Kommerzialisierungspartner für fünf mRNA-Proteinersatztherapien bei seltenen Erkrankungen; 50:50 globale Kosten- und Gewinnaufteilung
- Fünf exklusive Onkologie-LNP-Lizenzen für BioNTech. Genevant ist berechtigt, bedeutende kommerzielle Meilensteine für die Onkologie-Lizenzen zu erhalten

Pfizer

- Seit 2018 bestehende Lizenzierungsvereinbarung zur gemeinsamen Entwicklung eines prophylaktischen Grippe-Impfstoffs auf mRNA-Basis (BNT161)
- Vorabzahlung, Kapitalinvestition und erste Meilensteinzahlungen in Höhe von 120 Mio. \$
- Bis zu 325 Mio. \$ an möglichen weiteren Meilensteinzahlungen
- Lizenzgebühren auf weltweiten Absatz auf weltweiten Nettoumsatz im Falle einer Marktzulassung

University of Pennsylvania (UPenn)

- Seit 2018 strategische Forschungs- und Entwicklungskooperation mit der exklusiven Option, mRNA-Immuntherapien zur Behandlung von bis zu zehn Indikationen von Infektionskrankheiten zu entwickeln und zu vermarkten
- Unterstützung der Forschungsaktivitäten seitens BioNTech mit 20 Mio. \$
- UPenn führt die präklinischen Studien durch
- BioNTech behält die Option, die mRNA-Impfstoffkandidaten für die klinische Entwicklung zu lizenziieren

Bill & Melinda Gates Foundation

- Seit 2019 Forschungs- und Entwicklungsvereinbarung im Bereich HIV und Tuberkulose (TB) sowie bis zu drei weiteren Infektionskrankheiten
- 55 Mio. \$ als Equity-Investition in die Entwicklung weiterer Strategien zur Prävention und/oder Behandlung von HIV und TB
- Zuschüsse in Höhe von bis zu 45 Mio. \$ zur Finanzierung zusätzlicher Aktivitäten in bis zu drei weiteren Projekten im Bereich Infektionskrankheiten innerhalb der ersten fünf Jahre der Zusammenarbeit

Epitop, welches in Bauchspeicheldrüsenkrebs und anderen gastrointestinalen Krebsarten exprimiert wird und dort eine Rolle bei der Tumорadhäsion und Metastasenbildung spielt.

Im Juni 2019 gab BioNTech den Start der klinischen Entwicklung von Produktkandidat DuoBody®-PD-L1x4-1BB bekannt. PD-L1x4-1BB ist ein bi-

spezifischer Antikörper, der gemeinsam mit Genma A/S entwickelt wird. Im Rahmen der Phase-1/2a-Studie wird der bi-spezifische Antikörper in Patienten mit metastasierenden oder chirurgisch nicht entfernbarer soliden Tumoren getestet, die nicht mit der Standardtherapie behandelt werden können. Der DuoBody®-PD-L1x4-1BB ist der erste gemeinsam entwickelte Produktkandidat, der die klinische Phase erreicht. Die Kosten und Gewinne, die im Zuge der Partnerschaft anfallen, werden im Verhältnis 50 zu 50 geteilt. Ziel der 2015 unterzeichneten und 2016 um weitere Zielstrukturen und Technologien erweiterten Zusammenarbeit ist die Entwicklung und Vermarktung mehrerer neuartiger bi-spezifischer Antikörper mit überlegener in-vivo-Wirksamkeit, die das Immunsystem spezifisch gegen Krebszellen aktivieren.

Im September 2019 hat BioNTech eine Partnerschaft mit der Bill & Melinda Gates Stiftung für die Entwicklung von HIV- und Tuberkulose Impfstoffen bekanntgegeben. Im Rahmen dieser Vereinbarung hat BioNTech im September 2019 eine erste Kapitalinvestition in Höhe von 49.864 T€ (55.000 T\$) erhalten. Die Finanzierung dient der Entwicklung von präklinischen Impfstoffen sowie Immuntherapiekandidaten für HIV- und Tuberkulose Infektionen, die präventiv eingesetzt werden und im Fall von HIV eine dauerhafte Remission ohne antiretrovirale Therapie ermöglichen sollen. Durch zusätzliche zukünftige Finanzierungsverein-

barungen könnten sich die Gesamtinvestitionen der Gates Stiftung auf bis zu 100.000 T\$. belaufen. In diesem Fall wird dieses Kapital für die klinische Entwicklung von Produktkandidaten sowie der Initiierung neuer Projekte in diesem Indikationsbereich verwendet werden.

Finanzierung

KAPITALERHÖHUNG SERIES B

Im Juni und August 2019 hat BioNTech die Series-B-Finanzierungsrounde abgeschlossen, um seine individualisierte Krebsmedizinpipeline weiterzuentwickeln. Hierbei handelt es sich um eine der größten Einzelfinanzierungen eines privaten europäischen Biotechnologieunternehmens. In diesem Zusammenhang gab BioNTech insgesamt 12.465.288 Stammaktien (mit Ausnahme von 5.524.506 Stammaktien, die an einen in Hongkong ansässigen Investor ausgegeben und anschließend aufgrund keiner Gegenleistung wieder an BioNTech übertragen wurden; diese Aktien werden als eigene Anteile gehalten) an neue sowie bestehende Aktionäre zu einem Preis von 18,10 \$ pro Aktie für einen Gesamterlös von 198.548 T€ (225.622 T\$) aus. Die Kapitalerhöhung erhöhte das gezeichnete Kapital um 17.990 T€ und die Kapitalrücklage um 186.390 T€ sowie die Erfassung von eigenen Anteilen in Höhe von 5.525 T€.

BÖRSENGANG („INITIAL PUBLIC OFFERING – IPO“)
Am 10. Oktober 2019 erhöhte BioNTech in Verbindung mit dem Börsengang das gezeichnete Kapital um 10.000 T€. American Depository Shares (ADS), die Stammaktien repräsentieren, wurden an der Nasdaq Global Select Market zu einem Preis von 15,00 \$ angeboten. Am 6. November 2019 erhöhte BioNTech das gezeichnete Kapital um weitere 517 T€ durch die Ausübung der im Zusammenhang mit dem

Die nachstehende Tabelle gibt eine Übersicht zu 2019 und 2018 an Vorstandsmitglieder ausgegebenen Aktienoptionen, die in den Geschäftsjahren

	Zeitpunkt der Ausgabe ¹	Anzahl der den Aktienoptionen zugrunde liegenden Stammaktien ⁴	Ausübungspreis (€)	Ablauf der Möglichkeit zur Optionsausübung
Prof. Dr. Ugur Sahin	15.11.2018	1.830.348	10,14	17.9.2026
	10.10.2019 ²	4.374.963	13,60	11.10.2029
Sean Marett	15.11.2018	610.110	10,14	17.9.2026
Dr. Sierk Poetting	15.11.2018	610.110	10,14	17.9.2026
Dr. med. Özlem Türeci	15.11.2018 ³	1.952.334	10,14	17.9.2026

¹ Wenn nicht anders angegeben, werden alle Optionen am 16. September 2022 unverfallbar.


² Die Option wird jährlich in gleichen Raten nach vier Jahren, jeweils am 10. Oktober in den Jahren 2020, 2021, 2022 und 2023, unverfallbar.

³ Die Optionen wurden am 16. März 2019 unverfallbar, gleichwohl kann die Ausübung erst ab dem 16. September 2022 erfolgen.


⁴ Die Anzahl der Stammaktien bildet den Effekt der Kapitalerhöhung aufgrund eines Aktiensplits von 1:18 ab, der Am 8. September 2019 mit der Eintragung im Handelsregister wirksam wurde.


Link Analysis

Simple extract of links between Gates Foundation and other NGOs /GOVs





WHO – World Health Organization






CARB-X






WGHA - Washington Global Health Alliance




Almost all of these individuals' employers receive donations from the Gates Foundation.


**WGHA - Washington Global Health Alliance
AND
Board Members of
University of Washington -
Department of Health**




MMV




Adjvant Capital




Merck




Merck + Jule Louise Gerberding (direct connections)




Pfizer




Johnson & Johnson




IVI - International Vaccine Institute




ID2020




BMGF - Bill & Melinda Gates Fou...




ONE




IFPMA - International Federation of Pharmaceutical Manufacturers & Associations




PharmAccess Foundation







CGD - Center for Global Development



NTI - Nuclear Threat Initiative (1 Level)



NTI - Nuclear Threat Initiative
+ Direct Linked Persons (1 Level)



NTI - Nuclear Threat Initiative (Addintional Information)

<https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/>

<https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/biosecurity-innovation-and-risk-reduction-initiative-launch/>


https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf

https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf


https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf

https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf


CSIS - Center for Strategic and International Studies / Strengthening America's Health Security



CSIS - Center for Strategic and International Studies / Strengthening America's Health Security




GVP - Global Virome Project - 1 Level Connections




https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

GVP - Global Virome Project (Level 2 Connections)




https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

METABIOTA (Level 2 Connections)




IHME - The Institute for Health Metrics and Evaluation




<http://www.healthdata.org/about/governance/board>

IHME - The Institute for Health Metrics and Evaluation incl. direct connections of Members



DARPA




Pentagon tasks Pfizer with radically rethinking vaccine development - <https://www.fiercepharma.com/r-d/pentagon-tasks-pfizer-radically-rethinking-vaccine-development> (2013-12-09)

BARDA - Rapidly advancing a Zika mRNA vaccine / DARPA – Advancing mRNA therapies and vaccines for biodefense


- <https://www.modernatx.com/ecosystem/strategic-collaborators/mrna-strategic-collaborators-government-organizations> (09/2016 & 10/2013)

Selected Views


Peter Piot
 Lothar Wieler
 Victor Dzau
 Georg F Gao
 Jeremy Ferrar
 Christian Drosten
 Ralph S. Baric
 Peter Daszak




CDC - 1 Level



CDC - Director / Former Director - 1 Level



Contributors of selected documents



1 - Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 <https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930418-9>


2 - Leopoldina-Stellungnahmen zur Coronavirus-Pandemie (2020) <https://www.leopoldina.org/publikationen/detailansicht/publication/leopoldina-stellungnahmen-zur-coronavirus-pandemie-2020/>

3 - Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020 <https://apps.who.int/iris/rest/bitstreams/1266309/retrieve>


4 - Document - The Global Virome Project https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

5 - Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR (2020-01-13) https://www.who.int/docs/default-source/coronavirus/e/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2


The Global Virome Project




The Global Virome Project




Peter Piot & Heidi Larson - additional links




Ralph S. Baric - 1 Level







Selected Persons - Event Atlantic Storm / Clade-X / Event 201 / Dark Winter




YGL - Young Global Leaders - 1 Level




Selected Persons - YGL



YGL Members and their direct connection to existing objects.




Tara O'Toole and In-Q-Tel



IT

Google



Facebook



Mark Zuckerberg



Nilmini Rubin



Regina Dugan



Sheryl Sandberg

Founder and Chief Executive Officer of Facebook (2017-2018)



Poynter Institute



Munich Security Conference / Si...



Facebook Journalism Project



FullFact



FactCheck.org



WEF - World Economic Forum

International Affairs Manager Facebook (2017-2018)


GF

Grants Grants Sponsor of WEF


Red arrows pointing from the four entities above to the three entities below.

“EXERCISES”


Dark Winter (2001)



Atlantic Storm (2005)




Clade-X (2018)




https://www.centerforhealthsecurity.org/our-work/events/2018_clade_x_exercise/
<https://www.weforum.org/agenda/2018/07/infectious-disease-pandemic-clade-x-johns-hopkins/>

Event 201 (2019-10-18)




NTI - 2018-07-20/21 - Constructive discussion during the June 20-21, 2018 Meeting on biological risk hosted by the Wellcome Trust, NTI, and the World Economic Forum in London



List of participants not available...

<https://www.nti.org/newsroom/news/nti-bio-partners-wellcome-trust-and-world-economic-forum-host-meeting-biosecurity-innovation-and-risk-reduction/>

NTI - 2018-10-29 - Biosecurity Innovation and Risk Reduction Initiative Launch



<https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/>

https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf

https://media.nti.org/documents/Initiative_Participants_and_Initiative_Members_List_October_29_Kickoff.pdf

https://media.nti.org/documents/NTI_Paper_5_Establishing_a_Seal_of_Approval_to_Incentivize_Adherence_to_Biosec_a5iL1rO.pdf

https://media.nti.org/documents/NTI_Initiative - Paper_2 - Instituting_Biosecurity_Investment.pdf


https://media.nti.org/documents/NTI_Initiative - Paper_6 - Additional_Topics_for_Potential_Discussion.pdf

https://media.nti.org/documents/NTI_Initiative - 3 - Standards_for_Funders_and_Grantees_to_Identify.pdf

https://media.nti.org/documents/NTI_Initiative - Paper_4 - Insurance_Incentives_for Reducing_Biological_Risks.pdf

https://media.nti.org/documents/NTI_Initiative - Paper_1 - Universal_Platform_to_Prevent_Illlicit_Gene_Synthesis_zVnWfjM.pdf

NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events Munich Security Conference




https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf

https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf


https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf

NTI - 2019-05-29 - bio Focuses on High-Consequence, Deliberate, and Global Catastrophic Biological Risks During World Health Assembly Side Event




<https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/>

NTI - 2019-12-xx - Washington, DC Tabletop Exercise Participants




NTI - 2020-02-xx - 2020 Munich Security Conference Tabletop Exercise Participants




Wilton Park - 2018-11-07/8/9 - Powerful actor, high impact bio-threats



Munich Security Conference / Sicherheitskonferenz München




Members of several
Advisory Boards and
related
exercises/events




“Meetings”

Public Congress on Global Health for
CDU/CSU Parliamentary Group
2019-05-08




2021-01-12/32 Some Future forum on Preparedness (SCHMIDT FUTURES)




“Gang”


BMGF Scientific Advisory Committee




Commission's advisory panel on COVID-19 (E03719)




Eurosurveillance editorial board (2 Level)




International Advisory Board on Global Health




NTI - Expert Contributors to Scenario Development




RKI Robert Koch Institut - Scientific Advisory Board for the Centre for International Health Protection (ZIG)



Connections between Georg F. Gao (Chinese CDC), Chris Elias (Gates Foundation), Christian Drosten (Charite), Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust)



Connections between Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust), Joachim Sauer (Leopoldina), Georg F. Gao (Chinese CDC), Peter Piot (Commissions Advisory Panel, Gates Foundation Senior Fellow),, Christian Drosten (Charite), Chris Elias (Gates Foundation), Ilona Kickbusch, Hans-Ulrich Holtherm (BGM)



Commission's advisory panel on COVID-19 (E03719)

<https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupId=3719&fromMeetings=true&meetingId=20410>

International Advisory Board on Global Health

<https://www.bundesgesundheitsministerium.de/english-version/press/international-advisory-board.html>

CDU / CSU - Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

<https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten>

NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events
Munich Security Conference

Sample of Public Private Partnership

Open Letter to Biden Administration – 3rd August 2021

“US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security”

https://healthpolicy.duke.edu/sites/default/files/2021-08/USEPCR%20Cover%20letter_FINAL_For%20Distribution.pdf

US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security

We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been [fully vaccinated](#).

To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough.

We are in a global war against a virus that doesn't respect borders and rapidly advances across continents. If the virus continues to circulate largely unchecked in many parts of the world, there is a very real prospect of new variants emerging that could totally pierce vaccine immunity, returning America and the rest of the world to square one.

The only way to prevent such a catastrophe is to dramatically decrease cases and slow transmission of the virus through widespread global vaccination, combined with other public health measures. Inequitable access to high-quality vaccines threatens to prolong the pandemic and destabilize economies and societies around the world.

To [date](#), 82 percent of all COVID-19 vaccine doses that have gone into arms worldwide have been administered in high- and upper middle-income countries. By contrast, less than one percent have been administered in low-income countries. Meanwhile, COVAX, the multinational vaccine facility, is struggling to meet this challenge, having [distributed](#) only 153 million doses out of 4.1 billion administered [worldwide](#).

We are facing the very real possibility that low- and lower-middle income countries will be stuck at low vaccine coverage levels through 2022 and beyond, an outcome that will be deadly. The deep divide between vaccine haves and have-nots is a challenge to our conscience and a major threat to our economic recovery and national security.

Fortunately, the supply of high-quality vaccines produced by US and allied manufacturers is [projected](#) to exceed 7 billion doses in 2021 and 14 billion doses in 2022 – more than enough to protect Americans and vaccinate the world. But doing so will require coordinated action by the US, other nations, and manufacturers to finance, allocate, and deliver doses where they are most acutely needed.

The US is on track to have over 1 billion excess doses, even assuming vaccinations and boosters for the entire population. This means we can combat the Delta-driven surge at home, while at the same time donating doses to combat it abroad. Indeed, we can – and must – do both simultaneously. This world war requires a global plan of attack.

The US and G7 allies have taken important but modest steps to close the global vaccine gap, including by accelerating large-scale production and delivery of high-quality vaccines, increasing financial support to COVAX, and committing to share roughly 900 million doses over the next year (including 580 million from the US). But these actions fall far short of the true scale and urgency required.

Much more needs to be done to provide high-quality vaccines more quickly, and to build countries' vaccine distribution and delivery capacity, which is rapidly becoming the key constraint in the race between vaccines and variants.

With the global situation becoming more dire, and current global efforts proving to be woefully insufficient, urgent US leadership is needed to get doses into arms, galvanize global action, and protect our national security. That is why **we call on President Biden to:**

- **Host a presidential-level "Global Vaccination Summit"** before the UN General Assembly meeting in September; the Summit should bring together public and private sector leaders from around the world, especially from low- and lower-middle income countries, and secure commitments to take the needed actions to close vaccine supply gaps and address financing and capacity gaps in vaccine distribution, delivery, and demand generation;
- **Rally global leaders to commit before or at the Summit to meeting the goal of vaccinating 70 percent of the world's population by mid-2022;** and
- **Launch a US Emergency Plan for Global COVID-19 Relief to help achieve that goal** and augment multilateral efforts, including the COVAX/WHO-coordinated global response and regionally-led efforts such as [the Africa Vaccine Acquisition Task Team \(AVATT\)](#).

The US Emergency Plan for Global COVID-19 Relief should be White House-led, spearheaded by a Global COVID-19 Emergency Response Coordinator reporting to the President and supported by a special inter-agency task force. Its main objectives should be to:

- Strengthen global coordination of vaccine supply chains and manufacturing.** Greater transparency and accountability in the vaccine marketplace are essential. The US should press for the development of comprehensive monthly estimates of global vaccine input availability (e.g., bioreactors, lipids, filters) and vaccine supply for the coming 12-18 months, so that the US and other countries will have assurances of sufficient doses for future domestic needs, while also maximizing the amount of high-quality vaccines available for global use;
- Increase US donations to at least 1 billion doses by mid-2022**, including 500 million in 2021, and push other high-income countries to substantially increase donations, so that the US and G7/EU allies collectively donate 1-2 billion doses by the end of 2021;
- Accelerate globally distributed manufacturing capacity for vaccines and vaccine inputs** by providing financial and technical assistance, and facilitating private sector licensing and knowledge transfer, including for mRNA platform vaccines, to ramp up vaccine manufacturing capabilities in Africa, Latin America, and Asia; and by reaching a global agreement on reducing the use of export restrictions for COVID-19 vaccines, therapeutics, diagnostics, and related inputs; and
- Most critically, ensure that doses are translated into vaccinations, and strengthen health systems and preparedness for future pandemics**, by accelerating a US-led effort to increase vaccine distribution and delivery capacity, and increase vaccine confidence and demand, in countries with the highest burden of disease, lowest vaccination rates, and least resources, augmenting and complementing multilateral efforts by the development banks, Access to COVID-19 Tools Accelerator and COVAX, Africa Centers for Disease Control, and others.

While these steps can and should be implemented now, they would benefit from additional Congressional support. The administration and Congress should urgently work to advance legislation to fund and sustain a comprehensive international COVID-19 response as well as health systems strengthening and pandemic preparedness efforts.

This plan should be implemented to serve as a catalyst and model for efforts by other high-income nations to use their excess vaccine supplies and technical capabilities to augment the global response. In addition, while focused on the present crisis, this plan should evolve to become part of a permanent initiative to increase preparedness for future pandemics.

This US Emergency Plan for Global COVID-19 Relief reflects both our ideals as a people and our interests as a nation. By galvanizing global efforts to vaccinate the population of the world's poorest, most afflicted countries, it will accelerate the end of the pandemic – here and everywhere.

Please read the full report, [US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security](#), to learn more.

Signed By



Amanda Glassman
Executive Vice President,
Center for Global
Development; CEO of CGD
Europe; and Senior Fellow

Rachel Silverman
Policy Fellow, Center for
Global Development

Prashant Yadav
Senior Fellow, Center for
Global Development

J. Stephen Morrison
Senior Vice President and
Director, Global Health Policy
Center, CSIS

Katherine Bliss
Senior Fellow, Global Health
Policy Center, CSIS

Anjali Balakrishna
Program Director, COVID
Collaborative

Anna McCaffrey
Fellow, Global Health Policy
Center, CSIS

Gary Edson
President, COVID
Collaborative

John Bridgeland
CEO, COVID Collaborative

Michael Merson
Wolfgang Joklik Professor of
Global Health, Duke Global
Health Institute, Duke
University

Mark McClellan
Director, Duke-Margolis
Center for Health Policy,
Duke University

Krishna Udayakumar
Director, Duke Global Health
Innovation Center, Duke
University

Bruce Gellin
Chief, Global Public Health
Strategy, The Rockefeller
Foundation

Endorsed By

Thomas Bollyky
Senior Fellow, Council on
Foreign Relations

Scott Gottlieb
Resident Fellow, American
Enterprise Institute, and
former Commissioner of the
US Food and Drug
Administration

Carolyn Reynolds
Co-Founder, Pandemic
Action Network, and Senior
Associate, Global Health
Policy Center, CSIS

William Frist
Former U.S. Senator (R-TN)
and Former Senate Majority
Leader

**Margaret (Peggy)
Hamburg**
Former Commissioner of the
US Food and Drug
Administration, former
Foreign Secretary of the
National Academy of
Medicine

Helene Gayle
President and Chief Executive
Officer, The Chicago
Community Trust


Amb [ret] Jimmy Kolker
Former Assistant Secretary,
Global Affairs, Department of
Health and Human Services

Jack Leslie
Chairman, Weber Shandwick

Following People/NGOs were part of open letter to Biden Administration, 3rd August 2021

Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky


“US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security”




Following People/NGOs were part of open letter to Biden Administration, 3rd August 2021

Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky

Extended by their relations to Gates Foundation, Wellcome Trust and others.




Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA




	A	B	C	D	E	F	G	H	I	J	K	L	M	N	
1															
2															
3	Sum of GrantsAmountTotal		Column Labels												
4	Row Labels		2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021 Grand Total	
5	Albert B. Sabin Vaccine Institute		7.897.985	12.085.497	6.071.478		18.636.252	20.000	20.000	3.163.373	7.435.542	641.879	1.166.367	390.000	57.528.373
6	Bill & Melinda Gates Foundation		7.897.985	12.085.497	6.071.478		18.636.252	20.000	20.000	3.163.373	7.435.542	641.879	673.577	390.000	57.035.583
7	GSK												352.600	352.600	
8	Wellcome Trust												140.190	140.190	
9	American Enterprise Institute		475.536	1.262.124		1.316.217	159.335	1.157.579				900.000	250.000	5.520.791	
10	Bill & Melinda Gates Foundation		445.496	1.068.788		1.316.217	159.335	1.157.579				900.000	250.000	5.297.415	
11	Robert Wood Johnson Foundation		30.040	193.336										223.376	
12	Center for Global Development		5.763.186		5.498.167	2.098.745	3.503.659	7.343.503	7.987.488	21.429.999	5.322.972	10.215.198	146.002	69.308.919	
13	Bill & Melinda Gates Foundation		5.763.186		5.148.167	914.025	3.503.659	4.343.503	6.187.488	21.380.057	1.164.534	8.415.198		56.819.817	
14	Open Philanthropy				350.000	1.184.720		3.000.000	1.800.000	49.942	4.158.438	1.800.000		12.343.100	
15	Wellcome Trust												146.002	146.002	
16	Center for Strategic and International Studies		8.145.677		1.000.000		9.537.181		8.074.000			3.761.211		30.518.069	
17	Bill & Melinda Gates Foundation		8.145.677		1.000.000		9.537.181		8.074.000			3.398.855		30.155.713	
18	Open Philanthropy											118.307		118.307	
19	Robert Wood Johnson Foundation											244.049		244.049	
20	Charité - Universitätsmedizin Berlin										549.999	1.086.181	259.550	1.895.730	
21	Bill & Melinda Gates Foundation										549.999	86.181	249.550	885.730	
22	Wellcome Trust										1.000.000	10.000		1.010.000	
23	Chatham House		191.935		282.631	1.095.403	356.938	146.617	136.700	434.118	116.569			2.760.911	
24	Bill & Melinda Gates Foundation		191.935		282.631	1.095.403	307.288	146.617	136.700	434.118	116.569			2.711.261	
25	Wellcome Trust						49.650							49.650	
26	Coalition for Epidemic Preparedness Innovations (CEPI)							183.362	101.277.016	80.680.175	4.059.969	20.000.000		206.200.522	
27	Bill & Melinda Gates Foundation								100.000.000			20.000.000		120.000.000	
28	Wellcome Trust							183.362	1.277.016	80.680.175	4.059.969			86.200.522	
29	Council on Foreign Relations		530.000	400.000		53.100		1.000.000			183.197	700.294	698.403	3.564.994	
30	Bill & Melinda Gates Foundation		530.000	400.000				1.000.000			183.197	700.294	698.403	3.511.894	
31	Robert Wood Johnson Foundation					53.100								53.100	
32	European Commission							500.000			45.178.000	500.000		46.178.000	
33	Bill & Melinda Gates Foundation							500.000			45.178.000	500.000		46.178.000	
34	London School of Hygiene & Tropical Medicine		32.242.822	35.296.421	18.183.902	28.592.802	23.075.855	34.897.169	28.408.827	68.092.466	32.161.719	21.726.570	21.000.078	9.823.615	353.502.246
35	Bill & Melinda Gates Foundation		21.601.425	18.672.120	1.836.336	13.123.576	10.448.820	22.056.301	14.478.175	39.982.036	19.408.074	16.359.406	7.362.722		185.328.991
36	Wellcome Trust		10.641.397	16.624.301	16.347.566	15.469.226	12.627.035	12.840.868	13.930.652	28.110.430	12.753.645	5.367.164	13.637.356	9.823.615	168.173.255
37	Nuclear Threat Initiative								6.726.859	5.461.715			9.500.045		21.688.619
38	Bill & Melinda Gates Foundation								250.000				1.000.045		1.250.045
39	Open Philanthropy								6.476.859	5.461.715			8.500.000		20.438.574
40	Pfizer			96.462					17.252.854						17.349.316
41	Bill & Melinda Gates Foundation								17.252.854						17.252.854
42	Wellcome Trust			96.462											96.462
43	Robert Koch Institut									38.317		253.000			291.317
44	Bill & Melinda Gates Foundation										253.000				253.000
45	Wellcome Trust									38.317					38.317
46	World Health Organization		44.012.053	72.270.654	200.885.383	399.386.075	645.774.522	197.178.706	118.061.247	234.127.556	284.599.026	217.274.610	298.952.191	112.880.895	2.825.402.918
47	Bill & Melinda Gates Foundation		44.012.053	71.993.007	200.885.383	399.366.566	642.616.767	195.112.242	117.048.753	234.086.580	277.644.327	213.837.542	296.027.811	99.743.257	2.792.374.288
48	Robert Wood Johnson Foundation									448.830		429.829	451.543		1.330.202
49	Wellcome Trust		277.647		19.509	3.157.755	2.066.464	563.664	40.976	6.524.870	2.985.525	2.924.380	13.137.638	31.698.428	
50	Grand Total		84.152.860	134.758.906	226.899.349	434.759.675	692.050.094	245.652.988	174.073.989	429.623.775	432.752.293	296.742.947	366.304.934	123.938.915	3.641.710.725


Media



Luminate + Child Objects 1 Level connection




<https://firstdraftnews.org>



Misc



BanQu Inc.
Investor of Change.org



[BanQu Inc. :: Minnesota \(US\) :: OpenCorporates](#)

BanQu Inc. BRANCH

Company Number a372c8f0-1fd4-e511-8164-00155d01c56d

Native Company Number [873011800028](#)

Status Active

Incorporation Date 15 February 2016 (over 5 years ago)

Company Type Business Corporation (Foreign)

Jurisdiction Minnesota (US)

Branch Branch of BANQU, INC. (Delaware (US))

Registered Address
1010 Dale St N
St Paul
55117-5603
MN
USA

Governing Legislation 303

Agent Name National Registered Agents, Inc



[642 Simon Ave - Google Maps](#)

[- Back](#)
THE WORLD ECONOMIC FORUM | FEBRUARY 16, 2021
BanQu is in The Circulars Accelerator 2021 Cohort



Change.org

Abbott Diabetes Care Sales Corporation

BRANCH

Company Number b96428df-8dd4-e011-a886-001ec94ffe7f

Native Company Number 1899138-3

Status Active

Incorporation Date 16 June 2006 (almost 15 years ago)

Company Type Business Corporation (Foreign)

Jurisdiction Minnesota (US)

Branch Branch of ABBOTT DIABETES CARE SALES CORPORATION (Delaware (US))

Registered Address
1010 Dale St N
St Paul
55117-5603
MN
USA

Governing Legislation 303

Agent Name C T Corporation System Inc

Directors / Officers C T Corporation System Inc, agent

Jared Watkin, chief executive officer

Registry Page <https://mblsportal.sos.state.mn.us/Bu...>

[Abbott Diabetes Care Sales Corporation :: Minnesota \(US\) :: OpenCorporates](#)

[Company officers with names matching 'C T Corporation System Inc' :: Page 1 :: OpenCorporates](#)

C T Corporation has several hundred branches of various companies registered here. Interesting: There are some pharmaceutical companies registered here. C T Corporation is a part of Walter Kluwer Group.


ROADMAP FOR THE IMPLEMENTATION OF ACTIONS BY THE EUROPEAN COMMISSION BASED ON THE COMMISSION COMMUNICATION AND THE COUNCIL RECOMMENDATION ON STRENGTHENING COOPERATION AGAINST VACCINE PREVENTABLE DISEASES

ACTIONS	TIMELINES AND DELIVERABLES				
	2018	2019	2020	2021	2022
Examine the feasibility of developing a common vaccination card/passport for EU citizens (that takes into account potentially different national vaccination schedules and), that is compatible with electronic immunisation information systems and recognised for use across borders, without duplicating work at national level. CR 16 and CC*			Feasibility study for the development of a common EU vaccination card		Commission proposal for a common vaccination card/passport for EU citizens
Produce on a regular basis a Report on the State of Vaccine Confidence in the EU , to monitor attitudes to vaccination. Based on that report and taking into account related work by WHO, present guidance that can support Member States in countering vaccine hesitancy. CR 17 and CC		State of Vaccine Confidence in the EU 2020 Follow up of the study published in October 2018 https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf	Guidance on countering vaccine hesitancy tailored to specific needs identified by the Member States and/or vaccine specific issues	Special Eurobarometer - Europeans' attitudes towards vaccination https://ec.europa.eu/publicopinion/index.cfm/surveysurveydetail/instruments/special/surveyy/2223	


* Basis for action:
CR for Council Recommendation and the number of the Recommendation in the legal text. CC for Commission Communication

“Selected Person”


Chris (Christopher) Elias




Lothar H. Wieler




Margret A. Hamburg




Christian Drosten




Scott Gottlieb





Anthony Fauci




Ralph S. Baric









Matthew Hepburn




Sharyl Sandberg




Peter Piot




Heidi Larson




Emer Cooke




Georg F. Gao




Ilona Kickbusch







Matthew Hepburn



Julie Louise Gerberding



Peter Daszak




Joe Cerrell




BMGF - Bill & Melinda Gates Fou...


Shah joined the Bill & Melinda Gates Foundation in 2001, serving in a range of roles as Managing Director, Global Policy and Advocacy, Bill & Melinda Gates Foundation.




Richard Danzig




Beth Cameron




Avril Haines




Amelia Fawcett




Muhammed Pate




Victor Dzau



Richard Hatchett



Elhadj As Sy



John Nkengasong

